Takeda pays $5M upfront to license antibodies for celiac disease drug development
Takeda is working on adding another celiac disease candidate to its pipeline, inking a licensing deal with Innate Pharma, allowing it to use a panel of antibodies to research and develop antibody-drug conjugates (ADCs).
In exchange for exclusive worldwide rights to whatever ADCs are developed using a selection of Innate’s antibodies, Takeda will give Innate a $5 million upfront payment with the potential for $410 million in milestones, plus royalties on net sales of any product resulting from the license.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
